Fennec Pharmaceuticals Inc. (FENC) Earnings
Fennec Pharmaceuticals Inc. is expected to report next earnings on August 13, 2026 (in NaN days), with a consensus EPS estimate of $0.01. FENC has beaten EPS estimates in 2 of its last 12 reported quarters (average surprise -81.3% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 14, 2026 | $-0.02 | $0.01 | +150.0% | $15M | +8.6% |
| Mar 24, 2026 | $0.03 | $-0.11 | -466.7% | $14M | -5.8% |
| Nov 13, 2025 | $-0.08 | $-0.02 | +75.0% | $12M | -15.2% |
| Aug 14, 2025 | $-0.06 | $-0.11 | -83.3% | $10M | +0.9% |
| Mar 10, 2025 | $0.56 | $-0.06 | -110.7% | $8M | +1.6% |
| Nov 7, 2024 | $-0.13 | $-0.21 | -61.5% | $7M | -12.9% |
| Aug 13, 2024 | $0.06 | $-0.20 | -433.3% | $7M | -34.3% |
| Mar 21, 2024 | $-0.02 | $-0.10 | -400.0% | $10M | +12.3% |
| Aug 3, 2023 | $-0.18 | $-0.21 | -16.7% | $3M | -47.5% |
| May 11, 2023 | $-0.21 | $-0.23 | -9.5% | $2M | -9.4% |
| Nov 11, 2022 | $-0.17 | $-0.31 | -82.4% | — | — |
| Aug 12, 2022 | $-0.10 | $-0.19 | -90.0% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 14, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Organizational Updates: Chief Commercial Officer Terry Evans joined the call for the first time after joining Fennec in Q4 2024, having already led reshaping and strengthening of the commercial organization. Chief Medical Officer Dr. Pierre Sayad joined for the Q&A session. - Clinical Development: Three investigator-initiated trials (IST) of Pedmark have been initiated at leading U.S. cancer centers to test the treatment in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers. Four abstracts on Pedmark were accepted for presentation at the 2026 ASCO annual meeting. Pedmark is currently approved for pediatric patients and holds a 2A NCCN recommendation for AYA patients. Positive informal meetings with Japan's PMDA were held in Q1, and the company continues to explore partnership opportunities in Japan. - Commercial Strategy: In late Q4 2025, the company launched Project Ignite, a commercial optimization initiative that expanded the sales force to 14 new territories and added 4 new frontline managers. This expanded the target prescriber base from 1,300 to over 5,000. Recruitment and onboarding concluded in early March 2026, with Q1 focused on foundational ramp-up work. - Market Access & Patient Support: Progress includes a new partnership with a major U.S. oncology GPO to integrate Pedmark across the network. Fennecures, the company's full-service patient support hub, facilitated a 48% quarter-over-quarter increase in completed infusions in Q1. Conversion of prospective patients to therapy hit the 80% target benchmark for the first time, with patient adherence also holding at ~80%. The site-of-care mix is evenly split (50% in-office, 50% at-home infusion), supporting broad access. Early Q2 data shows April demand alone was more than 50% of total Q1 Fennecures demand, with Q2 on track to exceed Q1 performance. - Financial Position: As of March 31, 2026, cash and cash equivalents totaled $40.1 million, up $3.3 million quarter-over-quarter, driven by $2.3 million in positive operating cash flow and $1 million from option exercises. The company generated positive operating cash flow in Q1 2026.
Guidance
- Full-year 2026 cash operating expenditures are expected to total ~$50 million, with over 60% of these expenses incurred in the first half of the year. - The company expects sequential quarterly cash position swings: Q2 ending cash is projected to be lower than Q1, but cash will return to positive growth in Q3 and grow through the second half of 2026. As revenue grows, operating income is expected to increase meaningfully in future quarters due to the company's predominantly fixed cost base. - Current cash, cash equivalents, investment securities, and projected Pedmark revenue are sufficient to fund operations under the company's current 2026 operating plan. - Partner Norgene is expected to launch Pedmark in approximately 10 new international markets in 2026, laying the foundation for future royalty and milestone revenue. No German milestone payment is expected in 2026, but the next milestone is targeted for the end of 2026. - Full productivity from the Project Ignite sales force expansion is expected in the second half of 2026, following a standard ramp-up period.
Segment performance
Fennec Pharmaceuticals operates with a single core product segment: Pedmark (PEDMARC), an ototoxicity prevention treatment for patients receiving cisplatin-based chemotherapy. For Q1 2026, net product sales of Pedmark totaled $15.1 million, representing a 73% year-over-year increase from $8.8 million in Q1 2025. This marks the sixth consecutive quarter of net sales growth for Pedmark. No other product segments are reported in the earnings call.
Risks & headwinds
- Forward-looking statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from projections, with detailed risks disclosed in the company's SEC filings. - Clinical data from newly initiated ISTs has not yet been generated, and there is no guarantee that new data will lead to expanded regulatory labeling, broader NCCN guideline recommendations, or increased commercial adoption. - The sales force expansion requires a ramp-up period, and productivity may not meet management expectations. - International milestones and revenue from partner Norgene are dependent on Norgene's successful launch execution, and the expected 2026 German milestone will not be achieved as previously anticipated. - Revenue collection cycles may cause quarterly cash position volatility.
Analyst Q&A
Q: What drove Q1 performance upside, and is growth coming from new accounts, deeper utilization of existing accounts, or early productivity from the expanded sales force? /
A: Growth stems from Project Ignite's expansion of sales reach and frequency, paired with strong performance from the Fennecures patient support program. Growth is balanced across academic centers and community practices, as well as both pediatric and AYA patient populations. Early April 2026 data already shows healthy contribution from new territories added via the expansion. /
Q: Why did the company pursue investigator-initiated trials for AYA and adult testicular cancer, and what impact do these trials have on commercial adoption and label expansion? /
A: The original Phase 3 trials that gained approval for Pedmark were conducted exclusively in pediatric populations, so AYA and adult physicians request additional population-specific data to support prescribing. These trials are investigator-initiated and led by KOLs at top academic centers. Once an IST launches at an institution, cross-functional engagement builds institutional awareness and comfort with Pedmark, leading to immediate increased commercial use, while mature data can be used for future NCCN guideline updates and regulatory expansion conversations. /
Q: What percentage of new growth is driven by new sales hires, when will they reach full productivity, and what is the current share of revenue via Fennecures and the stability of pediatric revenue? /
A: A significant number of new patients in the weeks following the March sales force onboarding have come from the new territories, with a healthy balance of growth in both new and existing accounts. New sales reps began full activity in mid-March, and full productivity is expected in the second half of 2026 following a standard ramp-up. Approximately 50% of current demand flows through Fennecures, and the share is growing as implementation improves. Pediatric revenue continues to grow (slower than AYA growth) as institutional acceptance from AYA adoption spills over to pediatric prescribing. /
Q: What is the company's life cycle management strategy for Pedmark, and what is its appetite for acquiring new assets? /
A: Life cycle management focuses on expanding use of Pedmark to new patient populations (AYA, adults, metastatic disease) across additional cisplatin-treated tumor types (head and neck, cervical, lung, bladder) via IST-generated data, with the goal of securing broader NCCN recommendations and potential regulatory label expansion. The company has significantly expanded its commercial organization and is actively open to acquiring complementary assets to layer onto its existing infrastructure.